>> “We will continue, obviously, to consider any kind of potential bolt-on acquisitions that could support and strengthen our portfolio. But, as we said, not if it’s a game to dilute our activities,” Bernard said.
Qiagen’s products include several types of COVID-19 tests that helped it recover after struggles in 2019, but it plans to keep growing sales even after the pandemic by making sure each new coronavirus-related product has other applications as well.
According to Bernard, Qiagen should grow sales of its automated, digital PCR and tuberculosis testing solutions by 20-150% in 2021 as the pandemic helped it bring its products to new markets.
“We have gained potentially one or two years of market growth as regards instrument placement,” Bernard said.
According to analysts, these improvements are “important” and make Qiagen less likely to see a sharp post-COVID-19 share price correction compared to its competitors. <<